When Can We Avoid Postmastectomy Radiation Following Primary Systemic Therapy?
Purpose of Review
Postmastectomy radiation therapy (PMRT) has been shown to reduce the risk of locoregional recurrences (LRR) and of distant metastases (DM) and to improve breast cancer–specific survival (BCSS) as well as overall survival (OS) in patients with locally advanced breast cancer who are considered high risk because of large tumors (> 5 cm) and/or presence of axillary lymph node involvement.
Controversy is still ongoing with respect to the indication of PMRT in the case of earlier stage invasive tumors in the presence of risk factors including young age, premenopausal status, presence of lymphovascular invasion (LVI), high tumor grade, or tumor size 2–5 cm. Simultaneously, the evolution of our understanding of breast cancer biology has led us to better identify patients for whom the administration of systemic treatment prior to surgery reduces tumor load, not only in the case of locally advanced tumors but also for earlier stages, namely in the case of unfavorable molecular subtypes. The role of PMRT in the context of these patients treated with primary systemic therapy (PST), especially after a good tumor response, is under evaluation by various studies.
This review identifies factors that may permit PMRT omission in a selected group of patients after PST.
KeywordsBreast cancer Mastectomy Postmastectomy radiation therapy Primary systemic therapy Lymph node irradiation
Compliance with Ethical Standards
Conflict of Interest
The authors declare they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 4.Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82(3):247–53.PubMedGoogle Scholar
- 5.Li Y, Moran MS, Huo Q, Yang Q, Haffty BG. Post-mastectomy radiotherapy for breast cancer patients with T1-T2 and 1-3 positive lymph nodes: a meta-analysis. PLoS One. 2013;8(12):1–9.Google Scholar
- 8.• Francis SR, Frandsen J, Kokeny KE, Gaffney DK, Poppe MM. Outcomes and utilization of postmastectomy radiotherapy for T3N0 breast cancers. Breast. 2017;32:156–61 A review based upon NCDB data focused on the use of PMRT in large and negative lymph nodes breast tumors (T3N0) suggesting survival advantage. PubMedGoogle Scholar
- 9.• Cassidy RJ, Liu Y, Kahn ST, Jegadeesh NK, Liu X, Subhedar PD, et al. The role of postmastectomy radiotherapy in women with pathologic T3N0M0 breast cancer. Cancer. 2017;54(PROC):1–2 Based upon data from NCDB (National Cancer Database), this review confirms benefit in overall survival with PMRT in pT3N0 tumors. Google Scholar
- 13.• Wang-Lopez Q, et al. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer? Crit Rev Oncol Hematol. 2015;95(1):88–104 Pathologic complete response (pCR) after PST has been suggested to be predictive of survival in breast cancer, although this fact remains a subject of controversy. This well-presented review addresses on the importance of an adequate definition of pCR and its significance in breast cancer outcomes. PubMedGoogle Scholar
- 15.Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.PubMedGoogle Scholar
- 16.Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84.PubMedGoogle Scholar
- 17.Swain SM, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;2017:646–53.Google Scholar
- 18.Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet Oncol. 2014;384:164–72.Google Scholar
- 19.Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg. 2015;262(3):434–8.PubMedPubMedCentralGoogle Scholar
- 20.• Chapman CH, Jagsi R. Postmastectomy radiotherapy after neoadjuvant chemotherapy: a review of the evidence. Oncology (Williston Park). 2015;29(9):657–66 This paper nicely reviews current evidence regarding PMRT use after PST and emphasizing the most controversial aspects and future directions . Google Scholar
- 22.Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;22(23):4691–9.PubMedGoogle Scholar
- 24.McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SWC, Yu TK, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68(4):1004–9.PubMedPubMedCentralGoogle Scholar
- 30.Boughey JC, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2017;263(4):802–7.Google Scholar
- 32.Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072–8.PubMedPubMedCentralGoogle Scholar
- 33.El H, et al. Refining the performance of sentinel lymph node biopsy post-neoadjuvant chemotherapy in patients with pathologically proven pre-treatment node-positive breast cancer : an update for clinical practice. Anticancer Res. 2016;1472:42–52.Google Scholar
- 36.Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–6.PubMedPubMedCentralGoogle Scholar
- 38.Diaz DA, Hurley J, Reis I, Takita C, Zhao W, Wright J. Locoregional outcomes in clinical stage IIB breast cancer after neoadjuvant therapy and mastectomy with or without radiation. Medicine (Baltimore). 2014;93(29):e230.Google Scholar
- 39.Shim SJ, Park W, Huh SJ, Choi DH, Shin KH, Lee NK, et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys. 2014;88(1):65–72.PubMedGoogle Scholar
- 40.Meattini I, Cecchini S, di Cataldo V, Saieva C, Francolini G, Scotti V, et al. Postmastectomy radiotherapy for locally advanced breast cancer receiving neoadjuvant chemotherapy. Biomed Res Int. 2014;2014:1–12.Google Scholar
- 43.Liu J, Mao K, Jiang S, Jiang W, Chen K, Kim BY, et al. The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. Oncotarget. 2016;7(17):24848–59.PubMedGoogle Scholar
- 44.Rusthoven CG, Rabinovitch RA, Jones BL, Koshy M, Amini A, Yeh N, et al. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(5):818–27.Google Scholar
- 46.• Gillon P, Touati N, Breton-Callu C, Slaets L, Cameron D, Bonnefoi H. Factors predictive of locoregional recurrence following neoadjuvant chemotherapyin patients with large operable or locally advanced breast cancer: an analysis of the EORTC 10994/BIG 1-00 study. Eur J Cancer. 2017;79:226–34 The results of this randomized, international and multicentre study confirm as factors directly related to the prognosis after PST both the unfavorable molecular subtype and the absence of pCR . PubMedGoogle Scholar
- 48.• Ohri N, et al. Postmastectomy radiation in breast cancer patients with pathologically positive lymph nodes after neoadjuvant chemotherapy: usage rates and survival trends. Int J Radiat Oncol Biol Phys. 2017;99(3):549–59 Using data from NCDB including nearly 30,000 patients, the authors analyze the role and usage of PMRT after PST in patients ypN+ . PubMedPubMedCentralGoogle Scholar
- 50.Chen X, Xia F, Luo J, Ma J, Yang Z, Zhang L, et al. Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II-III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy. Onco Targets Ther. 2018;11:1973–80.PubMedPubMedCentralGoogle Scholar
- 54.Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, et al. T3 disease at presentation or pathologic involvement of four or more lymph nodespredict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(1):138–45.PubMedGoogle Scholar
- 55.Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized. J Clin Oncol. 2004;22(21):4247–54.PubMedGoogle Scholar
- 56.Truong PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61(5):1337–47.PubMedGoogle Scholar
- 57.NCT01872975, NSABP B51/Radiation Therapy Oncology Group (RTOG). Standard or comprehensive radiation therapy in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery, 2019.Google Scholar
- 58.NCT01901094, ALLIANCE A011202. Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy, 2019.Google Scholar